ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.691,32
0,05%
S&P 500
5.266,61
-0,76%
Dow Jones
39.078,55
-1,49%
Euro vs US Dollar
1,08095
-0,14%
Bitcoin
67.589,20
-2,19%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Quince Therapeutics Inc (QNCX)

  7. Quince Therapeutics Inc (QNCX) News

QNCX

Quince Therapeutics (QNCX)

Quince Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:QNCX
DatumZeitQuelleÜberschriftSymbolFirma
13/05/202413h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QNCXQuince Therapeutics Inc
13/05/202413h00Business WireQuince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:QNCXQuince Therapeutics Inc
06/05/202422h05Business WireQuince Therapeutics to Present at The Citizens JMP Life Sciences ConferenceNASDAQ:QNCXQuince Therapeutics Inc
01/04/202413h00Business WireQuince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial ResultsNASDAQ:QNCXQuince Therapeutics Inc
22/02/202413h00Business WireQuince Therapeutics Launches Scientific Advisory BoardNASDAQ:QNCXQuince Therapeutics Inc
15/02/202422h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNCXQuince Therapeutics Inc
15/02/202413h00Business WireQuince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of DirectorsNASDAQ:QNCXQuince Therapeutics Inc
07/02/202422h05Business WireQuince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:QNCXQuince Therapeutics Inc
02/02/202423h53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QNCXQuince Therapeutics Inc
05/01/202422h01Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:QNCXQuince Therapeutics Inc
04/01/202422h05Business WireQuince Therapeutics to Participate at Investor Events in January 2024NASDAQ:QNCXQuince Therapeutics Inc
03/01/202422h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNCXQuince Therapeutics Inc
22/12/202322h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNCXQuince Therapeutics Inc
15/12/202300h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QNCXQuince Therapeutics Inc
08/12/202322h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNCXQuince Therapeutics Inc
08/12/202300h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QNCXQuince Therapeutics Inc
01/12/202319h38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QNCXQuince Therapeutics Inc
26/10/202323h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QNCXQuince Therapeutics Inc
25/10/202301h42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QNCXQuince Therapeutics Inc
25/10/202301h34Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:QNCXQuince Therapeutics Inc
23/10/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNCXQuince Therapeutics Inc
23/10/202313h00Business WireQuince Therapeutics Completes Acquisition of EryDel S.p.A.NASDAQ:QNCXQuince Therapeutics Inc
28/09/202322h53Dow Jones NewsQuince Therapeutics to Advance Study of EryDex as FDA Lifts Application HoldNASDAQ:QNCXQuince Therapeutics Inc
28/09/202322h05Business WireU.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-TelangiectasiaNASDAQ:QNCXQuince Therapeutics Inc
06/09/202313h18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNCXQuince Therapeutics Inc
06/09/202313h00Business WireQuince Therapeutics Appoints Dr. Charles S. Ryan as PresidentNASDAQ:QNCXQuince Therapeutics Inc
01/09/202300h42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QNCXQuince Therapeutics Inc
18/08/202300h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QNCXQuince Therapeutics Inc
10/08/202323h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNCXQuince Therapeutics Inc
10/08/202322h05Business WireQuince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023NASDAQ:QNCXQuince Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:QNCX

Kürzlich von Ihnen besucht

TG
ALV
Allianz
FX
EURGBP
Euro vs Sterling
COIN
ETHUSD
Ethereum
DBI
DAX
DAX
NASDAQ
TSLA
Tesla
CCOM
US100
US Tech 100
AMEX
XLV
Health Care Select Sector
TG
TUI1
Tui
NASDAQ
AAPL
Apple
CCOM
US30
US 30
PM
XAUUSD
Gold vs US Dollar
TG
RHM
Rheinmetall
NYSE
MRK
Merck
NASDAQ
GOOGL
Alphabet
TG
LHA
Deutsche Lufthansa
NYSE
NKE
Nike
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten